Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1918
Peer-review started: November 26, 2023
First decision: January 24, 2024
Revised: February 6, 2024
Accepted: March 20, 2024
Article in press: March 20, 2024
Published online: April 16, 2024
Hypertriglyceridemia is the third leading cause of acute pancreatitis (AP), and its incidence is increasing. Due to its relatively insidious etiology, it is easy to be ignored in the early stages. In China, Chaiqin Chengqi Decoction (CQCQD) has long been employed for treating AP.
To evaluate the effectiveness of CQCQD in patients diagnosed with mild/ moderately severe hypertriglyceridemic AP (HTG-AP).
In this study, the clinical data of 39 patients with HTG-AP admitted from January 2019 to November 2022 were collected. The changes of blood lipids, gastro
Twenty patients were treated with the conventional HTG-AP regimen, and 19 patients were additionally treated with CQCQD. After receiving treatment, the triglycerides (TG) level of the CQCQD group was lower than that of the CQCQD group (3.14 ± 0.25 mmol/L vs 4.96 ± 0.47 mmol/L, P < 0.01). After 3 d of treatment, the patients in the CQCQD group had more bowel movements than the control group (2.51 ± 0.25 times vs 1.00 ± 0.17 times, P = 0.01). The gastrointestinal function of most patients returned to normal, and the acute gastrointestinal injury score was significantly lower than that of the control group (0.11 ± 0.07 vs 0.42 ± 0.11, P < 0.01).
In patients with HTG-AP, CQCQD can significantly reduce the TG level, shorten the recovery time of defecation, significantly improve the gastrointestinal function.
Core Tip: Applying Chaiqin Chengqi Decoction (CQCQD) for treating acute pancreatitis (AP) has a long-standing history in China. To validate the efficacy of CQCQD in treating hypertriglyceridemic AP (HTG-AP), we conducted a retrospective analysis of patients with HTG-AP treated at our hospital. We compared and analyzed changes in blood lipid levels, gastrointestinal symptoms, and abdominal pain before and after treatment. Following treatment, the CQCQD group exhibited significantly lower triglyceride levels compared to the control group (3.14 ± 0.25 mmol/L vs 4.96 ± 0.47 mmol/L, P < 0.01). Additionally, shortened defecation recovery time and a notable improvement in gastrointestinal function were observed.